Completed PHASE2 INTERVENTIONAL 5-arm NCT02250612

SYL040012, Treatment for Open Angle Glaucoma (SYLTAG)

A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension

Sponsor: Sylentis, S.A.

Conditions Ocular Hypertension Open Angle Glaucoma

Interventions 1 drop of 0.375% SYL040012 (bamosiran) 1 drop of 0.5 % timolol maleate 1 drop of 0.750% SYL040012 (bamosiran) 1 drop of 1.125% SYL040012 (bamosiran) 1 drop of 1.5% SYL040012 (bamosiran)

Updated 11 times since 2017 Last updated: Dec 11, 2020 Started: Oct 31, 2014 Primary completion: Aug 31, 2015 Completion: Jan 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ocular Hypertension and Open Angle Glaucoma and is currently completed. Sylentis, S.A. leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

11 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Feb 2021 — Dec 2022 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sylentis, S.A.

Data source: Sylentis, S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Artesia, United States , Barcelona, Spain , Freiburg im Breisgau, Germany , Jerez de la Frontera, Spain , Louisville, United States , Madrid, Spain , Magdeburg, Germany , Morrow, United States , München, Germany , Münster, Germany and 9 more locations